|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅱ trial of cetuximab and carboplatin in relapsed platinumsensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study显示文摘 | Secord AA Blessing JA Armstrong DK | 2008 | Gynecol Oncol2008，108，3： | 1 |
| 2 | Prolonged oral etoposide as second-line therapy for platinum-sensitive ovarian carcinoma a Gynecologic Oncology Group Study显示文摘 | Rose PG Blessing JA Mayer AR | 1998 | J Clin Oncol1998，16，2： | 1 |
| 3 | Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study显示文摘 | Curtin JP Blessing JA Soper JT | 2001 | Gynecol Oncol2001，83，2： | 1 |
| 4 | Phase Ⅲ study of cisplatin with or without paclitaxel in stage Ⅳb, recurrent, orpersistent squamous cell carcinoma of the cervix : a gynecologic oncology group study 显示文摘 | Moore DH Blessing JA McQuellon RP | 2004 | J Clin Oncol2004，22，15： | 1 |
| 5 | Fixed-dose rate geme- itabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase Ⅱ trial 显示文摘 | Hensley ML Blessing JA Mannel R | 2008 | Gynecol Oncol2008，109，3： | 1 |
| 6 | Phase Ⅱ evaluation of 9-aminocamptothecin(9-AC,NSC # 603071)in platinum-resistant ovarian and primary peritoneal carcinoma:A Gynecologic Oncology Group Study显示文摘 | Miller DS Blessing JA Waggoner S | 2005 | Gynecol Oncol2005，96，1： | 1 |
| 7 | Phase III study of cisplatin with or without paclitaxel in stage 2VB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study 显示文摘 | Moore 13H Blessing JA McQuellon RP | 2004 | J Clin Oneol2004，22，15： | 1 |
| 8 | Cisplatin,vinblastine,and bleomycin in advanced and recurrent ovarian germ cell tumors显示文摘 | Williams SD Blessing JA Liao S-Y | 1989 | Ann Intern Med1989，111，1： | 1 |
| 9 | Phase II trial of nab-paclitaxel in the treatment of recurrent orpersistent advanced cervix cancer: a gynecologic oncol- ogy group study显示文摘 | Alberts DS Blessing JA Landrum LM | 2012 | Gynecol Oncol2012，127，3： | 1 |
| 10 | Prolonged oral etoposide as second-line therapy for platinum-resistent and platinum-sen-sitive ovarian carcinoma: a GOG study显示文摘 | Rose PG Blessing JA Mayer AR | 1998 | J Glin Oncol1998，16，2： | 1 |
| 11 | Paclitax- el and cisplatin as first-line therapy in recurrent or ad- vanced squamous cell carcinoma of the cervix: a gyne- cologic oncology group study显示文摘 | Rose PG Blessing JA Gershenson DM | 1999 | J Clin Oncol1999，17，9： | 1 |
| 12 | Fixed-dose rate gemcitabineplus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma:a Gynecologic Oncology Group phase trial显示文摘 | Hensley ML Blessing JA Mannel R | 2008 | Gynecol Oncol2008，109，3： | 1 |
| 13 | Phase II trial of cetux-imab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression:a Gy-necologic Oncology Group study显示文摘 | Secord AA Blessing JA Armstrong DK | 2008 | Gynecol Oncol2008，108，3： | 1 |
| 14 | Phase Ⅱ study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix显示文摘 | Morris M Blessing JA Monk BJ | 2004 | J Clin Oncol2004，22，16： | 1 |
| 15 | Phase Ⅱ evaluation of 9-amino- camptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a gynecologic ontology group study显示文摘 | Miller DS Blessing JA Waggoner S | 2005 | Gynecol Oncol2005，96，1： | 1 |
| 16 | A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer:a Gynecologic Oncology Group study显示文摘 | Aghajanian C Blessing JA Darcy KM | 2009 | Gynecol Oncol2009，115，2： | 1 |
| 17 | Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study显示文摘 | Thigpen JT Blessing JA Olt G | 2003 | Gynecol Oncol2003，90，3： | 1 |
| 18 | Phase m study of cisplatin with or without paclitaxel in stage N B,recurrent,or persistent squamous cell carcinoma of the cervix:a gynecologic oncology group study显示文摘 | Moore DH Blessing JA McQuellon RP | 2004 | J Clin Oncol2004，22，15： | 1 |
| 19 | Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a GOG study 显示文摘 | McGuire WP Blessing JA Bookman MA | 2000 | J Clin Oncol2000，18，5： | 1 |
| 20 | Prognostic Factors in Early-Stage Uterine Sarcoma-A Gynecologic Oncology Group Study显示文摘 | Major FJ Blessing JA Silverberg SG | 1993 | Cancer1993，71，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员